The DOI matches its Crossref record.
Subsite Specificity of Memapsin 2 (β-Secretase): Implications for Inhibitor Design
Abstract
Memapsin 2 is the protease known as beta-secretase whose action on beta-amyloid precursor protein leads to the production of the beta-amyloid (Abeta) peptide. Since the accumulation of Abeta in the brain is a key event in the pathogenesis of Alzheimer's disease, memapsin 2 is an important target for the design of inhibitory drugs. Here we describe the residue preference for the subsites of memapsin 2. The relative k(cat)/K(M) values of residues in each of the eight subsites were determined by the relative initial cleavage rates of substrate mixtures as quantified by MALDI-TOF mass spectrometry. We found that each subsite can accommodate multiple residues. The S(1) subsite is the most stringent, preferring residues in the order of Leu > Phe > Met > Tyr. The preferences of other subsites are the following: S(2), Asp > Asn > Met; S(3), Ile > Val > Leu; S(4), Glu > Gln > Asp; S(1)', Met > Glu > Gln > Ala; S(2)', Val > Ile > Ala; S(3)', Leu > Trp > Ala; S(4)', Asp > Glu > Trp. In general, S subsites are more specific than the S' subsites. A peptide comprising the eight most favored residues (Glu-Ile-Asp-Leu-Met-Val-Leu-Asp) was found to be hydrolyzed with the highest k(cat)/K(M) value so far observed for memapsin 2. Residue preferences at four subsites were also studied by binding of memapsin 2 to a combinatorial inhibitor library. From 10 tight binding inhibitors, the consensus preferences were as follows: S(2), Asp and Glu; S(3), Leu and Ile; S(2)', Val; and S(3)', Glu and Gln. An inhibitor, OM00-3, Glu-Leu-Asp-LeuAla-Val-Glu-Phe (where the asterisk represents the hydroxyethylene tansition-state isostere), designed from the consensus residues, was found to be the most potent inhibitor of memapsin 2 so far reported (K(i) of 3.1 x 10(-10) M). A molecular model of OM00-3 binding to memapsin 2 revealed critical improvement of the interactions between inhibitor side chains with enzyme over a previous inhibitor, OM99-2 [Ghosh, A. K., et al. (2000) J. Am. Chem. Soc. 14, 3522-3523].
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Amyloid Beta: Structure, Biology and Structure-Based Therapeutic Development
Chen, G.-F., Xu, T.-H., Yan, Y., Zhou, Y.-R., Jiang, Y., Melcher, K., & Xu, H. E. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.28 · Cited by 1,965
Suh, Y.-H., & Checler, F. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.3.469 · Cited by 467
Strategies for disease modification in Alzheimer's disease
Citron, M. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1495 · Cited by 429
BACE1 (β-secretase) inhibitors for the treatment of Alzheimer's disease
Ghosh, A. K., & Osswald, H. L. (2014) · Chem. Soc. Rev. · doi:10.1039/c3cs60460h · Cited by 358
Self-citationWong, H.-K., Sakurai, T., Oyama, F., Kaneko, K., Wada, K., Miyazaki, H., Kurosawa, M., De Strooper, B., Saftig, P., & Nukina, N. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414648200 · Cited by 290
Developing β‐secretase inhibitors for treatment of Alzheimer’s disease
Ghosh, A. K., Brindisi, M., & Tang, J. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07476.x · Cited by 272
Self-citationLichtenthaler, S. F., Dominguez, D.-I., Westmeyer, G. G., Reiss, K., Haass, C., Saftig, P., De Strooper, B., & Seed, B. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303861200 · Cited by 206
The Neural Cell Adhesion Molecules L1 and CHL1 Are Cleaved by BACE1 Protease in Vivo
Zhou, L., Barão, S., Laga, M., Bockstael, K., Borgers, M., Gijsen, H., Annaert, W., Moechars, D., Mercken, M., Gevaer, K., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.377465 · Cited by 167
Bace2 Is a β Cell-Enriched Protease that Regulates Pancreatic β Cell Function and Mass
Esterházy, D., Stützer, I., Wang, H., Rechsteiner, M. P., Beauchamp, J., Döbeli, H., Hilpert, H., Matile, H., Prummer, M., Schmidt, A., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.06.018 · Cited by 135
Regulated Intramembrane Proteolysis of the Interleukin-1 Receptor II by α-, β-, and γ-Secretase
Kuhn, P.-H., Marjaux, E., Imhof, A., De Strooper, B., Haass, C., & Lichtenthaler, S. F. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700356200 · Cited by 120
The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimers Disease
Vassar, R., & Cole, S. (2007) · Current Genomics · doi:10.2174/138920207783769512 · Cited by 84
The beta secretase BACE1 regulates the expression of insulin receptor in the liver
Meakin, P. J., Mezzapesa, A., Benabou, E., Haas, M. E., Bonardo, B., Grino, M., Brunel, J.-M., Desbois-Mouthon, C., Biddinger, S. B., Govers, R., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03755-2 · Cited by 80
Shi, X.-P., Tugusheva, K., Bruce, J. E., Lucka, A., Wu, G.-X., Chen-Dodson, E., Price, E., Li, Y., Xu, M., Huang, Q., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209859200 · Cited by 70
Identification of BACE1 cleavage sites in human voltage-gated sodium channel beta 2 subunit
Gersbacher, M. T., Kim, D. Y., Bhattacharyya, R., & Kovacs, D. M. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-61 · Cited by 32
Spatiotemporal processing of neural cell adhesion molecules 1 and 2 by BACE1 in vivo
Kim, W., Watanabe, H., Lomoio, S., & Tesco, G. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100372 · Cited by 21
Metadata
- Authors
- Turner, R. T., Koelsch, G., Hong, L., Castenheira, P., Ghosh, A., & Tang, J.
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2001-08-01
- Volume
- 40
- Issue
- 34
- Pages
- 10001-10006
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- OpenAlex
- W2045445527
- Cited by
- 185
- References
- 0
- FWCI
- 7.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.